Table 2. Medications in the considered population.
| Medications | H | DM |
|---|---|---|
| Diabetes medications | - | 34 (100%) |
| Metformin | - | 11 (32.35%) |
| DPP-4 inhibitor | - | 1 (2.94%) |
| Insulin | - | 3 (8.82%) |
| Metformin + Sulfonylureas | - | 10 (29.41%) |
| Metformin + DPP-4 inhibitor | - | 2 (5.88%) |
| Metformin + Sulfonylureas + DPP-4 inhibitor | - | 1 (2.94%) |
| Metformin + Insulin | - | 6 (17.65%) |
| Antihypertensive drugs | - | 15 (44.12%) |
| ACE inhibitor | - | 3 (8.82%) |
| Calcium channel blocker (amlodipina) | - | 1 (2.94%) |
| Angiotensin II receptor antagonist | - | 6 (17.65%) |
| Hydrochlorothiazide | - | 1 (2.94%) |
| Hydrochlorothiazide + ACE inhibitor | - | 2 (5.88%) |
| Hydrochlorothiazide + Angiotensin II receptor antagonist | - | 2 (5.88%) |
| Hypolipidemic drug | - | 9 (14.71%) |
H = group with healthy subjects; DM = group with type 2 diabetes without neuropathy; ACE = angiotensin converting enzyme; DPP-4 = Dipeptidyl peptidase-4. The data are presented as number of subjects and percentage between rounded parentheses.